A nanomedicine of resiquimod polymer and a preparation method and application thereof
By blocking the amino group of rectimote and introducing ROS-responsive bonds, rectimote polymer nanomedicines were prepared, solving the problems of systemic toxicity and tumor selectivity of rectimote nanomedicines and achieving highly efficient anti-tumor therapeutic effects.
CN117257801BActive Publication Date: 2026-05-29CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY CHINESE ACADEMY OF SCIENCES
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY CHINESE ACADEMY OF SCIENCES
- Filing Date
- 2023-09-20
- Publication Date
- 2026-05-29
Smart Images
Figure CN117257801B_ABST
Abstract
The application discloses a resiquimod polymer nanodrug and a preparation method and application thereof, and belongs to the technical field of medicines. The resiquimod polymer nanodrug has a structure shown in formula 1, and as ROS response resiquimod prodrug nanodrug (R848NPs), realizes selective activation of the drug at a tumor site, effectively reduces drug toxicity, and has good antitumor effect. The R848NPs effectively reduce drug toxicity by closing the pharmacophore amino group of the small molecule drug resiquimod, avoid the occurrence of immune-related adverse reactions after systemic administration, and introduce a ROS response bond, so that the small molecule original drug R848 is released through the action of an endogenous stimulator ROS in a high ROS environment at the tumor site, and good efficacy is achieved. In addition, when the ROS response resiquimod prodrug nanodrug is combined with ultrasound and alphaPDL1, the tumor inhibition rate can reach 99.0%.
Need to check novelty before this filing date? Find Prior Art